Image de couverture de livre

Letter: Enhancing HCC Surveillance: GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety—Authors' Reply

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Gamal Shiha, Riham Soliman
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
par: Gamal Shiha, et autres
Publié: (2025)

Letter: Enhancing HCC Surveillance– GES Score Represents an Innovative Simple Effective Tool for Risk Stratification, Patient Safety and Reduced Anxiety
par: Ibrahima Gueye
Publié: (2025)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
par: Tanat Saeoui, et autres
Publié: (2025)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
par: Yu‐Sheng Lin, et autres
Publié: (2026)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
par: Daniel Q. Huang, et autres
Publié: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
par: Virginia Solitano, et autres
Publié: (2024)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
par: Teresa Seum, et autres
Publié: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
par: Eunice Yewon Lee, et autres
Publié: (2024)

Letter: Tumour Burden Score for Predicting Extrahepatic Metastasis in Hepatocellular Carcinoma After Curative Resection. Authors' Reply
par: Elisa Pinto, et autres
Publié: (2026)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
par: Lukas Burghart, et autres
Publié: (2026)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
par: Francisco Idalsoaga, et autres
Publié: (2025)

Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply
par: Nikolaj Torp, et autres
Publié: (2025)

Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply
par: Ankit Kumar, et autres
Publié: (2026)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
par: Christian Labenz, et autres
Publié: (2026)

Letter Regarding ‘Combined Lyon and Milan Scores Predict Gerd Management Outcome Better Than Either Score Alone or Their Individual Components’. Authors' Reply
par: Stefano Siboni, et autres
Publié: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
par: Shintaro Akiyama, et autres
Publié: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
par: J. M. Schattenberg, et autres
Publié: (2026)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
par: Irene Spinelli, et autres
Publié: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
par: Francisco Idalsoaga, et autres
Publié: (2025)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
par: Isabella Lurje, et autres
Publié: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
par: A. B. Fons, et autres
Publié: (2026)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC—Authors' Reply
par: Subin Heo, et autres
Publié: (2025)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
par: María Chaparro, et autres
Publié: (2024)

Letter: Disease Stage and Absolute Risk in Evaluating the Branched‐Chain Amino Acid to Tyrosine Ratio in Cirrhosis. Authors' Reply
par: Takao Miwa, et autres
Publié: (2026)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
par: Nina Dominik, et autres
Publié: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
par: Mohamed El‐Kassas, et autres
Publié: (2025)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
par: Conrado Fernandez‐Rodriguez, et autres
Publié: (2024)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
par: Ziheng Calvin Xu, et autres
Publié: (2025)

Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Reply
par: Péter Bacsur, et autres
Publié: (2024)

Letter: Antiviral Prophylaxis Mitigates HBV Reactivation Risk During Cancer Immunotherapy: Unresolved Challenges and Future Directions—Authors' Reply
par: Landon Long Chan, et autres
Publié: (2025)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
par: Simone Chin, et autres
Publié: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
par: Hong‐Li Liu, et autres
Publié: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
par: Yuki Utakata, et autres
Publié: (2026)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
par: Amol N. Patil, et autres
Publié: (2026)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
par: Luis Antonio Díaz, et autres
Publié: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy
par: Yu Jun Wong
Publié: (2025)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
par: Pinelopi Arvaniti, et autres
Publié: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
par: Alberto Ferrarese, et autres
Publié: (2025)